Inactive Instrument

Other languages Stellar Biotechnologies Inc Nasdaq

Equities

Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	11/05
Top Premarket Gainers	05/03
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	10/02
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	16/12
Top Premarket Decliners	13/12
Top Premarket Gainers	22/11
Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study	21/11
Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech?S ARDS Drug	25/23/25
Top Premarket Decliners	13/23/13
Sector Update: Health Care Stocks Decline in Late Afternoon	13/23/13
Sector Update: Health Care	13/23/13
Top Midday Gainers	12/23/12
Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government	12/23/12
Edesa Biotech to Implement 1-for-7 Reverse Share Split; Stock Declines	10/23/10
Edesa Biotech, Inc. Publishes Phase 2 Substudy Results of ARDS Drug Candidate	28/23/28
Edesa Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	10/23/10
Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens	28/23/28
Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	12/23/12
Edesa Biotech, Inc. to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting	17/23/17
Edesa Biotech, US FDA Agree on EB05 Phase 3 Trial's Primary Endpoint, Population	15/23/15

No results for this search